Brief: Stoke Therapeutics Announces That FDA Will Allow The Administration Of A Higher Single Dose Of Stk-001 (70Mg) In The Ongoing Phase 1/2A Monarch Study Of Children And Adolescents With Dravet Syndrome

Stoke Therapeutics

15/03/2023 11:53

March 15 (Reuters) - Stoke Therapeutics Inc  STOK.O :
    * STOKE THERAPEUTICS ANNOUNCES THAT FDA WILL ALLOW THE
ADMINISTRATION OF A HIGHER SINGLE DOSE OF STK-001 (70MG) IN THE
ONGOING PHASE 1/2A MONARCH STUDY OF CHILDREN AND ADOLESCENTS
WITH DRAVET SYNDROME
    * STOKE THERAPEUTICS INC - COMPANY REMAINS ON TRACK FOR ITS
PLANNED DATA READOUTS FROM PHASE 1/2A MONARCH AND ADMIRAL
STUDIES IN 2023
    * STOKE THERAPEUTICS INC - COMPANY EXPECTS TO COMPLETE THE
PHASE
1/2A STUDIES OF STK-001 IN 2023 IN ORDER TO INITIATE A PHASE 3
PROGRAM IN 2024

Source text for Eikon:  ID:nBw8cLJYMa 
Further company coverage:  STOK.O 

 ((Reuters.Briefs@thomsonreuters.com;;))